Please Wait...

BioClinica Names Dr. John Hubbard Chief Executive Officer

Pharmaceutical Veteran to Lead Global Provider of Specialty Clinical Trial Services

December 1, 2014

NEWTOWN, Pa. – December 1, 2014 – BioClinica®, Inc., a leading provider of specialty outsourced clinical trial services, announced today that it has appointed John Hubbard, Ph.D., FCP, as chief executive officer and a member of the board of directors.  A seasoned pharmaceutical executive, Dr. Hubbard, 58, will join the company from Pfizer Inc., where he has served as senior vice president and worldwide head of development operations.  Dr. Hubbard will assume the CEO position on January 5, 2015 from Mark Weinstein.

“John is ideally suited to lead BioClinica.  His breadth of experience in virtually every aspect of the drug development process gives him a unique understanding of our customers’ needs, and how BioClinica can support them in efficiently managing the complexities of their trials,” said Jeffrey McMullen, chairman, BioClinica.

He added, “On behalf of the board, I’d like to thank Mark for his years of service to BioClinica.  He has done an outstanding job of bringing together BioClinica and CCBR-SYNARC’s capabilities following their merger earlier this year.  The company is strongly positioned to offer customers a comprehensive suite of clinical trial solutions, including imaging services, patient recruitment, cardiac safety and eClinical services.”

During his 30-year career, Dr. Hubbard has spearheaded pharmaceutical research and development initiatives for some of the industry’s premier organizations.  At Pfizer, he was responsible for more than 450 Phase 1-4 clinical projects per year.  He also served on the taskforce that redesigned Pfizer’s research and development organization.  Prior to Pfizer, Dr. Hubbard was group president of ICON plc’s clinical research services business, the company’s largest business division. During his tenure, ICON was named one of the country’s fastest growing companies by FORTUNE.  Dr. Hubbard also has held management positions at PAREXEL International Corporation, Revlon Health Care Group and Hoechst Marion Roussel Pharmaceuticals (now owned by Sanofi).

 “I am delighted to become part of the BioClinica organization.  We have a unique opportunity to partner with pharmaceutical companies and contract research organizations as they navigate unprecedented pressures, which I have experienced firsthand, and to improve the efficiency and effectiveness of drug development,” said Dr. Hubbard.  “BioClinica has exceptional scientific acumen, sophisticated technologies and specialized services that I believe will be instrumental in helping customers overcome these challenges and achieving their goals for bringing new products to market.”

Dr. Hubbard is a member of the Society of Clinical Pharmacology and Therapeutics, Drug Information Association and has served on its Special Interest Advisory Committee on Project Management.  He is a board certified diplomat in applied pharmacology and was elected as a fellow of the American College of Clinical Pharmacology (ACCP).  Dr. Hubbard has authored and co-authored articles and chapters on biopsychology, cardiovascular, clinical pharmacology and global drug development.  He received his bachelor’s degree in biopsychology from the University of Santa Clara and a doctorate from the University of Tennessee.  Dr. Hubbard was a National Institute of Health postdoctoral fellow in cardiovascular and clinical pharmacology at the University of Texas Health Sciences Center.

About Bioclinica

Bioclinica is a global life science provider that utilizes science and technology to bring clarity to clinical trials – helping companies to develop new life-improving therapies more efficiently and safely. Successful clinical trials require the ability to see key details and uncover hidden insights, and Bioclinica's hundreds of experienced scientific, medical, and domain experts bring unmatched insight across the development lifecycle, from the initial protocol to post-approval. The company's cloud-based offerings include medical imaging and cardiac safety services; clinical adjudication; randomization and trial supply management and optimization; electronic and eSource data capture; site and patient payments and budget forecasting; pharmacovigilance; trial management; and risk-based monitoring solutions. A true multifaceted partner to trial sponsors and Contract Research Organizations (CROs), Bioclinica offers a global network of research sites and patient recruitment services to provide committed, detail-focused service through all stages of drug development. The company's thousands of employees serve more than 400 pharmaceutical, biotechnology and device organizations – including all the top 20 biopharmaceutical companies and leading CROs – through a network of offices in the U.S., Europe, and Asia.

Learn more about Bioclinica and our Clinical Adjudication and other offerings at www.Bioclinica.com and in the Bioclinica Blog. Follow the latest company news and happenings on LinkedIn and Twitter.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Our clients have substantial success w #eSource, some spanning well over a decade. Still some in the industry remai… https://t.co/ASuUvN6xb9
bioclinica (Yesterday)
RT @RfwrightLSL: When Do You Think #BYOD (Bring Your Own Device) Will Become Widely Used To Capture PRO Data In #Clinical #Research? https:…
bioclinica (4 days ago)
ICYMI: Our V.P./Head of Neuroscience & Cardiovascular Svcs., Dr. Joyce Suhy, talks about challenges in determining… https://t.co/Lns6B3VPPN
bioclinica (4 days ago)
RT @FCR_News_Today: FDA Issues New Guides on Use of Electronic Health Information in #ClinicalTrials. #ClinicalResearch https://t.co/j8LHV2…
bioclinica (2 weeks ago)
RT @MySCRS: @AcurianCaresT2D, @bioclinica, @Medidata, @GreenphireINC, @PAREXEL: these are just some of this year's Global Summit exhibitors…
bioclinica (2 weeks ago)
Why choose a site network for clinical trials? https://t.co/CNGZcKYZ32 #Pharma
bioclinica (2 weeks ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen